Home » Newsletters » BioWorld Science

BioWorld Science

March 2, 2005

View Archived Issues

OX-22 completes efficacy study for insomnia

Mylan and King call off merger

Archimedes Pharma extends nasal drug delivery collaboration with Ionix

FDA extends PDUFA action date for nebivolol NDA

Orphan drug designation for Bronchitol in bronchiectasis

Sosei seeks Japanese approval for SOT-375

Intarcia begins phase III study for advanced breast cancer

MEM-3454 studied in phase I trial

BCY LifeSciences and Align sign agreement for DCF-987

Positive phase I findings for CYT006-AngQb for hypertension

Cytos Biotechnology reports 2004 achievements

Seikagaku completes phase I/II trial of SI-6603 for lumbar disc herniation

Recombinant human growth hormone studied in HIV+ patients with lipodystrophy

Tasmar receives European approval

Approvable letter for Glumetza

Second mutation in EGFR kinase domain confers resistance to gefitinib or erlotinib

Evidence supports the use of nicotine replacement therapies in heavy smokers

Allopurinol shows promise as add-on therapy for refractory schizophrenia

Chondroitinase shows promise in the management of spinal cord injuries

Prime-boost vaccine regimen active in infants of HIV-infected mothers

Extended treatment improves tacrolimus efficacy in myasthenia gravis

Modulators of amyloid beta levels claimed by Neurogenetics for Alzheimer's disease

Chemokine CCR5 receptor activators claimed by Ono

Eisai scientists disclose the neuroprotective activity of donepezil hydrochloride

Novel ALK-5 receptor inhibitors imparted by GSK

Bayer describes novel PDE9A inhibitors for Alzheimer's disease

AstraZeneca imparts the synthesis of three series of H+/K+-ATPase inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...